Article Text

PDF
The Glu228Ala polymorphism in the ligand-binding domain of death receptor 4 is not associated with rheumatoid arthritis
  1. B Yazdani-Biuki1,
  2. K Brickmann1,
  3. U Langsenlehner2,
  4. W Renner3,
  5. M Truschnig3,
  6. P Krippl2,
  7. F Fürst1,
  8. W B Graninger1,
  9. H-P Brezinschek1
  1. 1
    Department of Internal Medicine, Division of Rheumatology, Medical University of Graz, Austria
  2. 2
    General Hospital Fürstenfeld, Department of Internal Medicine, Austria
  3. 3
    Clinical Institute of Medical and Laboratory Diagnostics, Medical University of Graz, Austria
  1. Dr H-P Brezinschek, Department of Internal Medicine, Division of Rheumatology, Medical University of Graz, Auenbruggerplatz 32, 8036 Graz, Austria; hans-peter.brezinsek{at}meduni-graz.at

Statistics from Altmetric.com

Rheumatoid arthritis (RA) is a chronic inflammatory disease resulting in inflammation of the synovial lining and destruction of the adjacent bone and cartilage. Although the initiating event of RA is still unknown, recent research has demonstrated the importance of the increased production of tumour necrosis factor (TNF) α in the perpetuation of the inflammatory process of this disease. Targeting this molecule with soluble receptors—that is, etanercept, or antibodies, like infliximab or adalimumab, a new class of highly effective antirheumatic drugs has been developed. Unfortunately, not all patients respond sufficiently to TNF blockade or become unresponsive, and therefore …

View Full Text

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.